Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398592 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2745077 | 1.00 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL6108063 | 0.86 | HSD11B1 (0.33) | CHRNA7HSD11B1 | |
| SCHEMBL6108057 | 0.86 | HSD11B1 (0.33) | CHRNA7HSD11B1 | |
| SCHEMBL6106104 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL6106107 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL6106105 | 0.86 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL1425838 | 0.80 | NR1H2 (0.31) | POLB | |
| SCHEMBL23933653 | 0.79 | CHRNB2 (0.32) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 | |
| SCHEMBL2744190 | 0.79 | CHRNB2 (0.54) | CHRNB2CHRNB4CHRNA3CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149037-B2 | Pyrazole MAGL inhibitors | MAGI3, MAG, PYM1 | CHRNB2 3791/4885CHRNB4 4010/4885CHRNA3 2748/4885 |
| US-20200087304-A1 | PYRAZOLE MAGL INHIBITORS | MAGI3, MAG, PYM1 | CHRNB2 3791/4885CHRNB4 4010/4885CHRNA3 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.